RxDoctor Payments Data

Cecil Dodson, MD

Internal Medicine · Mountain Brk, ALNPI 1750493482

Payments from drug & device makers

$3,732in general payments, 2019–2025

Across 114 payments — averaging $32.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$739
  • AstraZeneca$480
  • GSK$360
  • Amarin Pharma, Inc.$344
  • Lilly USA, LLC$322
  • Bayer$286
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,714100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,732 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$51,162
Medicare patients
111
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$82,685
OzempicSemaglutide56$67,614
JardianceEmpagliflozin44$59,058
XareltoRivaroxaban44$27,749
Repatha SureclickEvolocumab26$22,976
JanuviaSitagliptin Phosphate16$21,206
MounjaroTirzepatide17$17,859
Synjardy XrEmpagliflozin/Metformin Hcl14$14,078
VascepaIcosapent Ethyl16$12,982
Icosapent Ethyl44$11,257
DexilantDexlansoprazole24$7,161
JanumetSitagliptin Phos/Metformin Hcl12$6,498
Pitavastatin Calcium15$4,158
Rosuvastatin Calcium237$4,118
Testosterone12$4,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$42$84,114113 claims
Boehringer IngelheimJardiance, Synjardy Xr$211$73,13758 claims
Novo NordiskOzempic$107$67,61456 claims
Johnson & JohnsonXarelto$12$27,74944 claims
MerckJanuvia, Janumet$131$27,70428 claims
Lilly USA, LLCMounjaro$322$17,85917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mountain Brk

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →